Iza-Bren BL-B01D1 EGFR HER3 Bispecific ADC for Recurrent Metastatic Nasopharyngeal Carcinoma NPC NMPA Approval China June 2026 Phase III BL-B01D1-303 Lancet ESMO Trial ORR PFS International Patients Second Line Third Line PD-1 PD-L1 Failure Baili Tianheng Bristol Myers Squibb
This guide explains iza-bren (伦康依隆妥单抗, BL-B01D1) — the first approved EGFR×HER3 bispecific antibody-drug conjugate for recurrent or metastatic nasopharyngeal carcinoma in China — covering mechanism of action, NMPA approval criteria, Phase III trial results, safety, pipeline indications, and what international NPC patients should ask before treatment planning or MDT review in China.
What Is Iza-Bren (BL-B01D1)? The First EGFR×HER3 Bispecific ADC Approved for Nasopharyngeal Carcinoma in China
A structured guide for international patients, caregivers, and physicians on iza-bren — how this first-in-class bispecific ADC works, who it is approved for, what the Phase III data showed, and what to consider before treatment planning
On 23 June 2026, China's NMPA approved iza-bren (伦康依隆妥单抗, BL-B01D1) for adults with recurrent or metastatic nasopharyngeal carcinoma (NPC) who have failed at least second-line systemic therapy including platinum chemotherapy and PD-1/PD-L1 inhibitors. It is the first globally approved EGFR×HER3 bispecific antibody-drug conjugate (ADC). This article explains what the approval means clinically — but a new drug is a tool in the treating physician's hands, not a treatment plan in itself. Whether iza-bren is appropriate for any individual patient can only be decided by a qualified oncologist who knows the full medical history.
Before anything else: reading about a newly approved drug does not mean a patient should request it, switch treatment, or travel for care on their own. Drugs — including iza-bren — are options that doctors evaluate, sequence, and prescribe within a full treatment plan. All decisions about starting, stopping, or changing therapy must follow the advice of the treating oncology team or a specialist who has reviewed the complete case.
Key points at a glance:
- •Iza-bren is a bispecific ADC targeting both EGFR and HER3, delivering a topoisomerase I inhibitor payload (Ed-04) with a drug-to-antibody ratio of 8
- •Approved in China for heavily pre-treated recurrent/metastatic NPC — not for all NPC stages or as first-line therapy
- •Phase III data (BL-B01D1-303, published in The Lancet) reported higher response rates and longer PFS vs physician's-choice chemotherapy in the studied population
- •Additional indications (oesophageal squamous cell carcinoma, triple-negative breast cancer) and other tumour types remain in development — approval status may expand over time
- •Individual eligibility requires specialist assessment — patients should not self-select this drug based on an approval announcement alone
- •All treatment decisions must be made with the treating physician; a drug approval creates a medical option, not an automatic recommendation
Why Later-Line NPC Treatment Options Matter
Nasopharyngeal carcinoma (NPC) is a head and neck cancer arising in the nasopharynx. It is uncommon globally but endemic in southern China, Southeast Asia, and parts of North Africa — and incidence is rising among migrant populations in Western countries. Most NPC is associated with Epstein-Barr virus (EBV) and is often treated initially with chemoradiation and immunotherapy combinations.
When recurrent or metastatic (R/M) disease develops after prior systemic therapy — particularly after platinum chemotherapy and PD-1/PD-L1 inhibitor treatment — options become limited. Prognosis in this setting has historically been poor, with five-year overall survival often reported below 10% in heavily pre-treated later-line populations. New targeted approaches in this setting address a clear unmet need, though individual outcomes remain variable.
Why China is a relevant context for NPC care
Southern Chinese oncology centres — including major centres in Guangzhou and other NPC-endemic regions — manage among the largest NPC caseloads worldwide. Specialist experience with relapsed NPC, EBV-associated disease, and later-line sequencing is concentrated in these centres. International patients from Southeast Asia and other high-incidence regions sometimes consider structured review or treatment planning in China when local later-line options are exhausted — but this requires individual medical assessment, not automatic travel.
How Does Iza-Bren Work as an EGFR×HER3 Bispecific ADC?
Iza-bren belongs to the antibody-drug conjugate (ADC) class — molecules that link a tumour-targeting antibody to a cytotoxic payload. The antibody directs the drug toward cancer cells; after internalisation, the payload is released to kill the cell. For a broader explanation of how ADCs fit into precision oncology, see our guide on how targeted cancer drugs work.
Dual targeting: EGFR and HER3
EGFR and HER3 are receptor proteins often overexpressed on epithelial tumours, including NPC. They participate in signalling pathways that promote tumour cell growth and survival. Iza-bren binds both receptors simultaneously, blocking downstream signalling and enabling selective delivery to cells expressing these targets.
Bispecific design and antigen heterogeneity
Tumours often show heterogeneous protein expression — some cells express one target more than another. Dual targeting may help address this variability and reduce the risk that downregulation of a single antigen allows cancer cells to escape treatment.
Payload and linker
Iza-bren uses Baili Tianheng's proprietary topoisomerase I inhibitor Ed-04, linked via an enzyme-cleavable linker, with a drug-to-antibody ratio (DAR) of 8. Topoisomerase I inhibitors interfere with DNA replication in dividing cells.
Skin toxicity consideration
The bispecific structure is designed to preferentially bind cells co-expressing EGFR and HER3, potentially reducing off-target effects on skin epithelial cells that express EGFR but low HER3 — a relevant design consideration because EGFR-targeted therapies can cause significant skin toxicity.
First-in-class context: iza-bren is described as the first EGFR×HER3 bispecific ADC to enter Phase III development and the first of this class to receive regulatory approval globally (China, June 2026). This does not mean it is appropriate for every patient with EGFR- or HER3-expressing cancer — eligibility depends on cancer type, prior treatment, and individual clinical factors.
Who Is the NMPA Approval For?
The June 2026 NMPA approval specifies the following patient population. This is a label summary — individual treatment decisions require physician assessment.
- Adult patients with recurrent or metastatic nasopharyngeal carcinoma
- Prior treatment: at least second-line systemic therapy
- Must have received a platinum-based chemotherapy regimen
- Must have received a PD-1 or PD-L1 inhibitor
- Histologically or cytologically confirmed disease
Important: this approval is for a specific later-line NPC population — not newly diagnosed, locally advanced, or first-relapse patients who may still have curative-intent or earlier-line options. Matching the label on paper is not the same as being the right patient for the drug. Only the treating physician — who understands prior responses, current disease burden, organ function, and the full treatment arc — can determine whether iza-bren belongs in the plan.
What Did the Phase III BL-B01D1-303 Trial Show?
Approval was based on the Phase III BL-B01D1-303 study (NCT06118333 / CTR20233419), presented as a late-breaking abstract at ESMO 2025 and published in The Lancet. This was a multicentre, randomised, open-label trial conducted at 55 hospitals in China.
Study design
- 386 patients randomised 1:1
- Ages 18–75; ECOG 0–1
- All had ≥2 prior systemic treatment lines; must include platinum + PD-1/PD-L1
- Iza-bren vs physician's choice chemotherapy (gemcitabine, capecitabine, or docetaxel)
- Primary endpoints: BICR-assessed ORR and overall survival (OS)
- Heavily pre-treated cohort: >40% had ≥3 prior lines; ~50% had liver, bone, or lung metastases at baseline
Key efficacy results (vs chemotherapy)
- cORR: 54.6% vs 27.0% (OR ≈ 3.33)
- Complete responses (CR) observed in the iza-bren arm
- Median DoR: 8.5 vs 4.8 months
- Median PFS: 8.38 vs 4.34 months (HR 0.44)
- Prespecified subgroup analyses suggested consistent PFS benefit across baseline subgroups (HR 0.29–0.50)
These results were reported in the trial population as of the data cutoff (March 2025). Trial outcomes in a study group do not predict individual patient response. Overall survival data maturity and long-term follow-up should be considered in treatment planning discussions with a specialist.
For patients whose disease has progressed after immunotherapy and multiple chemotherapy lines, this trial addresses a setting where options are often limited. A structured MDT second opinion can help determine whether iza-bren — or other later-line approaches — is medically appropriate for a specific case.
What About Safety?
In BL-B01D1-303, iza-bren was reported as generally manageable in the studied population. Treatment-related adverse events (TRAEs) leading to discontinuation occurred in 2.6% of iza-bren-treated patients, and no new safety signals were identified relative to known ADC class effects in the reported analysis.
ADC therapies as a class may cause haematologic suppression, gastrointestinal effects, fatigue, and other organ-specific toxicities depending on payload and target. Individual tolerance varies. All patients considering iza-bren should review expected side effects, monitoring requirements, and management plans with their treating oncology team before starting therapy.
Supportive care — including symptom management, nutrition, and emotional support — typically runs alongside active cancer treatment. For international patients in China, supportive approaches such as TCM may be coordinated within hospital systems to help manage fatigue, appetite, or recovery, but only alongside standard oncology treatment and with medical team approval.
Development Beyond NPC: Pipeline and Global Context
Iza-bren's approval timeline reflects priority review in China — accepted in November 2025 and approved approximately seven months after inclusion in the priority review pathway (application accepted August 2025). The drug has received multiple breakthrough therapy designations in China and breakthrough therapy designation in the United States.
In December 2023, Baili Tianheng entered a licensing agreement with Bristol Myers Squibb (BMS) valued at up to USD 8.4 billion, including an USD 800 million upfront payment. Baili Tianheng retains exclusive development rights in mainland China; BMS co-develops in the United States and holds exclusive rights in other global markets outside China.
Other indications in development
- Oesophageal squamous cell carcinoma (ESCC) — marketing application accepted by CDE (January 2026)
- Triple-negative breast cancer (TNBC) — marketing application accepted (June 2026)
- Phase III trials registered across additional tumour types including biliary tract, NSCLC, SCLC, urothelial, and ovarian cancers — data readouts will determine future regulatory paths
Pipeline activity does not mean iza-bren is approved or appropriate for all these cancer types today. Each indication requires its own clinical evidence and regulatory review.
What Should International NPC Patients Ask?
- →Have I received the prior therapies specified in the approved indication (platinum chemotherapy and PD-1/PD-L1 inhibitor)?
- →Is my disease confirmed as recurrent or metastatic NPC with adequate tissue documentation?
- →What were my responses and durations of response to prior lines — and why did each line stop?
- →What is my current performance status and organ function — am I eligible for ADC therapy?
- →Are there other later-line options (clinical trials, alternative chemotherapies, re-irradiation) that should be compared with iza-bren?
- →If considering care in China, does the treating centre have NPC specialist experience and access to iza-bren under current regulations?
- →What monitoring and supportive care plan would accompany treatment?
Patients from Vietnam, Malaysia, and other NPC-endemic regions may find relevant context in our guide for Vietnamese patients considering cancer care in China, which discusses relapsed NPC pathways at southern Chinese specialist centres. For broader later-line decision frameworks, see options when standard treatment fails and immunotherapy after treatment failure.
What Happens Next
A new drug approval adds a possible tool to the oncologist's armamentarium — it does not replace clinical judgment. For patients and caregivers, the appropriate response to news like this is to bring informed questions to the treating doctor, not to decide independently that this drug should be used.
For international families, the practical sequence usually begins with confirming diagnosis and full treatment history with the current oncology team, then — if the doctor agrees it may be worth exploring — requesting specialist review of whether iza-bren or other later-line options fit the individual case.
Evaluating Later-Line NPC Treatment Options in China?
If you or a family member has recurrent or metastatic nasopharyngeal carcinoma after prior chemotherapy and immunotherapy, a structured MDT review can help clarify whether iza-bren or other approaches may be appropriate — before any travel or treatment decision is made.
Request an MDT Case ReviewFrequently Asked Questions
What is iza-bren (BL-B01D1)?
Iza-bren (伦康依隆妥单抗, BL-B01D1) is a bispecific antibody-drug conjugate (ADC) that simultaneously targets EGFR and HER3. It delivers a topoisomerase I inhibitor payload to tumour cells through dual receptor binding and antibody-mediated internalisation. It is described as a first-in-class EGFR×HER3 bispecific ADC and received NMPA approval in China in June 2026 for recurrent or metastatic nasopharyngeal carcinoma after failure of at least second-line systemic therapy including platinum chemotherapy and PD-1/PD-L1 inhibitors.
Who is eligible for iza-bren in its approved NPC indication in China?
The approved indication covers adult patients with recurrent or metastatic nasopharyngeal carcinoma who have previously received at least second-line systemic treatment, including a platinum-based regimen and a PD-1 or PD-L1 inhibitor. Individual eligibility still depends on performance status, organ function, prior treatment details, and physician assessment. Patients should confirm eligibility with a qualified oncologist rather than self-assessing from the label alone.
What did the Phase III BL-B01D1-303 trial show?
In the Phase III BL-B01D1-303 study presented at ESMO 2025 and published in The Lancet, iza-bren was compared with physician's choice chemotherapy (gemcitabine, capecitabine, or docetaxel) in heavily pre-treated recurrent/metastatic NPC patients. The trial reported higher confirmed objective response rate (54.6% vs 27.0%), longer median duration of response (8.5 vs 4.8 months), and longer median progression-free survival (8.38 vs 4.34 months; HR 0.44) in the iza-bren arm. Results apply to the studied population and individual outcomes may differ.
Is iza-bren approved outside China?
As of its June 2026 NMPA approval, iza-bren's first regulatory approval was in China. Baili Tianheng and Bristol Myers Squibb have a global licensing arrangement under which development continues in the United States and other markets. Approval status outside China may differ and should be verified for each country. International patients should not assume global availability based on the China approval alone.
Can international patients access iza-bren treatment in China?
China has among the highest nasopharyngeal carcinoma caseloads globally, particularly in southern regions, and specialist centres often manage complex relapsed NPC. Whether an international patient can access iza-bren depends on medical eligibility, regulatory access pathways, hospital policy, and treatment planning — not on the approval alone. A structured MDT review based on pathology, prior therapy, and imaging is the appropriate first step before any travel decision.
Should patients ask their doctor for iza-bren after reading about the approval?
Patients may discuss the approval with their treating oncologist, but should not request or start iza-bren independently. A newly approved drug is a tool available to physicians — not a self-selected treatment. The treating doctor must evaluate whether it fits the patient's prior therapy history, current disease status, organ function, and overall treatment plan. All decisions to use, defer, or choose an alternative should follow physician advice.
Disclaimer: ChinaMed Waypoint is a coordination service, not a medical provider. Nothing in this article constitutes medical advice, a treatment recommendation, or a suggestion that any patient should receive iza-bren. New drug approvals describe what is medically possible under specific conditions — only a qualified oncologist or head and neck cancer specialist who knows the individual case can decide whether a drug should be used. All treatment decisions must follow physician advice.
Related Guides
How Targeted Cancer Drugs Work
Foundational guide to targeted therapy and antibody-drug conjugates for international patients.
What Options Exist When Standard Cancer Treatment Fails?
A decision framework for patients facing progression after chemotherapy, immunotherapy, or surgery.
Cancer Treatment in China for Vietnamese Patients
Includes context on relapsed nasopharyngeal carcinoma care at southern Chinese specialist centres.
Request a Structured NPC Treatment Review
If recurrent or metastatic nasopharyngeal carcinoma is progressing after prior therapy, a structured MDT consultation may help clarify whether iza-bren or other later-line options in China should be considered for your situation.